PropertyValue
?:abstract
  • Multisystem inflammatory syndrome (MIS-C) is a pediatric hyperinflammation disorder caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). It has now been reported from several countries the world over. Some of the clinical manifestations of MIS-C mimic Kawasaki disease (KD) shock syndrome. MIS-C develops 4–6 weeks following SARS-CoV-2 infection, and is presumably initiated by adaptive immune response. Though it has multisystem involvement, it is the cardiovascular manifestations that are most prominent. High titres of anti-SARS-CoV-2 antibodies are seen in these patients. As this is a new disease entity, its immunopathogenesis is not fully elucidated. Whether it has some overlap with KD is still unclear. Current treatment guidelines recommend use of intravenous immunoglobulin and high-dose corticosteroids as first-line treatment. Mortality rates of MIS-C are lower compared to adult forms of severe COVID-19 disease. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00296-020-04749-4) contains supplementary material, which is available to authorized users.
?:creator
?:doi
  • 10.1007/s00296-020-04749-4
?:doi
?:journal
  • Rheumatol_Int
?:license
  • no-cc
?:pdf_json_files
  • document_parses/pdf_json/d58cd58071d13d8106ae5f398fb6a6b139c4faac.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7680080.xml.json
?:pmcid
?:pmid
?:pmid
  • 33219837.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Medline; PMC
?:title
  • Severe COVID-19, multisystem inflammatory syndrome in children, and Kawasaki disease: immunological mechanisms, clinical manifestations and management
?:type
?:year
  • 2020-11-21

Metadata

Anon_0  
expand all